Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Fludarabine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 6/20 | 0.82 |
| ▸ | P2RY1 | P47900 | 8/20 | 0.73 |
| ▸ | P2RY11 | Q96G91 | 5/20 | 0.73 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.73 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.73 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine Phosphate SCHEMBL14565620 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL3511 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL1650192 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL13046080 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL17541855 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL482449 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL23884975 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL899922 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL8401646 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL30350656 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200129637-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2020-04-30 | — | — | US | disclosed |
| US-20190218291-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218291-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | ERBB2, ERBB3, AXL | CA5A 2032/4885NT5E 888/4885P2RY1 4163/4885 |
| US-20200129637-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | ERBB2, ERBB3, AXL | CA5A 2032/4885NT5E 888/4885P2RY1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.